Coronavirus: South Korea approves first home-made Covid-19 vaccine
- Clinical trials showed SK Bioscience’s two-dose SKYCovione vaccine appeared to be more effective than AstraZeneca shots in building immunity against infections
- Officials say protein vaccines like SKYCovione, similar to shots used for the common flu could appeal to people hesitant to use vaccines with newer technologies

In clinical trials involving some 4,000 participants in South Korea and five other countries, SK Bioscience’s two-dose SKYCovione vaccine appeared to be more effective than the broadly used AstraZeneca shots in building immunity against infections, officials at South Korea’s Food and Drug Safety Ministry said.
South Korea’s mass immunisation campaign has been mainly dependent on Pfizer and Moderna’s mRNA shots. But officials say protein vaccines like SKYCovione, which are similar to shots used for years against the common flu and hepatitis B, could appeal to people who are hesitant to use vaccines developed with newer technologies.
South Korea has eased most of its virus restrictions after battling an omicron surge earlier this year, but some experts say the country may see another rise in infections despite a high vaccination rate because of waning immunities and the possible emergence of new variants.
The country reported 10,463 new cases of the coronavirus on Wednesday, its first daily increase over 10,000 in 20 days. Health Ministry official Son Youngrae said during a separate briefing it’s too early to tell whether the country is facing another surge after a months-long downward trend.